DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on Decemb...( Ticker Symbol: CUR QUEBEC...),Health

    Ticker Symbol: CUR

QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Mr. John Schafer, President and CEO of the Company, will be presenting a company overview at the Piper Jaffray 20th annual Health Care Conference on Wednesday, December 3, 2008, at 4:00 PM (ET). This conference is taking place in New York (New York) on December 2 and 3, 2008.

The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations and Conferences. An archived presentation will be available on the Web site for 30 days.

More information on the Piper Jaffray 20th annual Health Care Conference can be found at www.piperjaffray.com.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Ca
'/>"/>